Verisante Signs Distribution Deal For Aura in UK and Ireland | GenomeWeb

Verisante Technology said this week that it has signed an exclusive agreement with Frontière Médicale EUROPE for distribution of its Verisante Aura skin cancer detection device in the UK and Ireland.

With the agreement, Verisante now has distribution agreements for the Aura in Canada, Germany, Austria, Liechtenstein, Switzerland, the UK, and Ireland. The company began sales of the device at the beginning of the year, and recognized $235,000 in revenue from it for the quarter ended March 21, 2013.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.